Colorectal Neoplasms
|
0.410 |
GeneticVariation
|
group |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Colorectal Neoplasms
|
0.410 |
Biomarker
|
group |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Colorectal Neoplasms
|
0.410 |
Biomarker
|
group |
BEFREE |
Thus, the pH-activatable SN-38-BOC micelle could serve as a promising candidate in colorectal tumor therapy.
|
31352923 |
2018 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Gastrointestinal Stromal Tumors
|
0.300 |
Biomarker
|
group |
CTD_human |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
|
27793025 |
2016 |
Gastrointestinal Stromal Sarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
|
27793025 |
2016 |
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Malignant neoplasm of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 14 previously unreported susceptibility loci for adolescent idiopathic scoliosis in Japanese.
|
31417091 |
2019 |
Adenoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 14 previously unreported susceptibility loci for adolescent idiopathic scoliosis in Japanese.
|
31417091 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
Childhood asthma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations.
|
23829686 |
2013 |
Hepatitis C
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules).
|
27990835 |
2017 |
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
The UDPS follow-up analysis demonstrated that the presence of BOC or TLP-RAVs persist one year after therapy cessation only in HCV GT 1a patients.
|
26971166 |
2016 |
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
The secondary objective was the evaluation of the percent of patients with negative HCV RNA at week 4 (RVR), 8 (RVR BOC), 12 (EVR), or at the end-of-treatment (ETR) that reached SVR.
|
25469044 |
2014 |